Postperfusion lung syndrome is an ischemia-reperfusion injury resulting in increased capillary permeability and the formation of variable degrees of non cardiogenic pulmonary edema after cardiopulmonary bypass (CPB). Its incidence has been markedly decreasing in comparison with the early CPB era. This is mostly due to improvement of the extracorporeal circulation equipment including oxygenator, blood pump, and arterial filter. Nevertheless, overt Adult Distress Respiratory Syndrome (ARDS) develops in 0.5% to 1.7% of the cases, with a mortality rate as high as 90% (1). More importantly a recent study by Boldt et al has reported that CPB still significantly increases extravascular lung water even if it is not accompanied by severe pulmonary dysfunction (2).
Lung transplant recipients often require cardiopulmonary bypass support during their surgical procedure, the most common indication being pulmonary hypertension, inability to tolerate single lung ventilation and hemodynamic instability. Reperfusion lung injury following orthotopic lung transplantation occurs in 10 to 20% of patients and is an important source of morbidity and mortality. Although most patients recover, severe graft dysfunction can be fatal, contributing to 13% of early deaths after transplatantion. Even when less severe, reperfusion injury prolongs ventilator time and the duration of intensive care unit stay, and also may be associated with an increase in the incidence of early rejection (3-5).
Postperfusion lung syndrome after CPB and reperfusion injury after lung transplantation have common clinical manifestations, resulting in severe pulmonary dysfunction and significant parenchymal infiltrate on chest radiograph. Differentiation between the two is often difficult even by pathologic approach. The mechanisms underlying the pulmonary tissue damage by these phenomena have been elucidated within the last decade. The damaging effect of CPB is mainly mediated by complement and leukocyte activation due to the foreign surfaces encountered by the blood and free radical generation. Cytokines are critical mediators of this inflammatory reaction. Ischemia-reperfusion lung injury is also mediated by free-radical production in the endothelium, which triggers polymorphonuclear leukocyte and complement activation. Cytokines play a fundamental role also in this setting.
Cytokine release during CPB
The systemic inflammatory response to cardiopulmonary bypass results in an increased production of IL-1 and TNF-α. The significance of detection of elevated levels of cytokines during cardiopulmonary bypass is that these humoral agents can serve as markers for ongoing tissue damage (6, 7). Leukocytosis, production of acute phase proteins, synthesis of the cell adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and IL-6 production are stimulated by release of IL-1. Similar effects are exerted by tumor necrosis factor-alpha and IL-6 itself. Finally, recently discovered post CPB interleukin-8 release results in an extremely potent chemoattractant activity for neutrophils, inducing pulmonary sequestration of neutrophils as in adult respiratory distress syndrome (8).
Cytokine release after lung transplantation
Lung allograft reperfusion also results in cytokine release. First reports of elevated levels of BAL IL-2, TNF-α, interferongamma and IL-6 after lung allotransplantation in animal models concluded that cytokine production was compartmentalized since no change was detected in the plasma levels (9, 10). Later Palace et al (11) demonstrated a transient release of TNF-α in the plasma after the initiation of reperfusion in a rat model. Interestingly the lung neuthrophil infiltration increased significantly after peak rise in TNF-α generation, suggesting its contribution in lung reperfusion injury. In clinical lung transplantation, Pham et al (12) measured the serum IL-6 level before and after reperfusion in patients who underwent heart-lung, double (DLT) or singlelung transplantation (SLT) and showed that it was minimal before implantation, peaked at 4 hours after reperfusion, and
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Heparin-coated conduits
In the attempt to ameliorate this inflammatory response many cardiopulmonary bypass strategies and materials have been tested. In this respect surface-bound heparin conduits have been extensively studied. Gu et al used heparin coated bypass circuits in routine cardiac surgery and found a decreased activation of systemic inflammatory mediators (14) . Consistent with this finding, Steinberg et al (15) observed that use of heparin-coated bypass circuits resulted in a significant reduction in circulating levels of interleukines, especially IL-6 and IL-8. Not of secondary importance is that heparin-coated bypass circuits allow low systemic heparinization which results in low post-operative blood loss.
Up to now, there has been only one experimental study on the use of a heparin-coated CPB system in a lung transplant model. Francalancia et al (16) investigated in a canine model of single lung allotransplantation whether cardiopulmonary bypass adversely affects early graft function and whether a heparin ionically-coated cardiopulmonary circuit with reduced systemic heparin dosage improves results compared with a standard uncoated cardiopulmonary bypass system. They found no significant advantage in the group treated with heparin-coated circuits in terms of partial pressure of oxygen, lung compliance, lung water content and pathological findings. Similarly post perfusion cardiac index, mean arterial pressure and postoperative blood loss were not significantly improved.
Although extracorporeal membrane oxygenation (ECMO) has become standard treatment for neonatal respiratory failure, the results in adults have been less encouraging. With technical improvements in membrane oxygenators and revised ECMO protocols, there has been renewed interest towards this therapeutic option in adults with severe acute respiratory failure. However, relatively few cases of ECMO as an adjunct to adult lung transplantation have been reported. Recently, a report by Zenati (17) et al reviewed the experience of the University of Pittsburgh with ECMO for primary severe allograft dysfunction in 8 patients after lung transplantation. They reported an 87% rate of successful weaning with a low incidence of complications. More recently Ko et al (18) reported their 5 patient experience of using ECMO instead of the conventional CPB during single lung transplantation for primitive pulmonary hpertension and extending its use into the early postoperative period. Due to the technical advances with heparin-bound circuits in the ECMO system they avoided the use of heparin in the first 24 hours except for an intravenous injection of 5000 units before cannulation. Stable intraoperative and postoperative cardiopulmonary function could be maintained under ECMO support. Significantly ECMO reduced blood flow to the transplanted lung and prevented over flow edema in the delicate early postoperative period. Four patients were successfully weaned. No major complication was reported. Interestingly, intraoperative use of ECMO mandated the use of a cell saver system for aspiration of blood from the operative field. This resulted not only in significantly reduced postoperative blood loss but also in lower humoral activation. These findings are in accordance with those of Boisclair et al and those from Onizuka et al who demonstrated the adverse effects of the retransfusion of the wound blood into the cardiotomy suction system of standard non-coated CPB equipment (19, 20) .
In conclusion, both ischemia-reperfusion lung injury and early lung allograft dysfunction syndrome appear to be mediated by the same reaction cascade, making it easily understandable that pulmonary grafts implanted under CPB are more suceptible to ischemic insult. As a consequence lung transplantation presents a unique setting in which to examine the effect of new modalities of extracorporeal perfusion.
L.S. DE SANTO
Department of Cardio-Thoracic and Respiratory Sciences, V. Monaldi Hospital, Second University of Naples, Naples -Italy Reprint requests to: Luca Salvatore De Santo, MD V. Monaldi Hospital V.L. Bianchi, 5 80131 Naples, Italy
